These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
360 related articles for article (PubMed ID: 16100648)
1. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients. Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648 [TBL] [Abstract][Full Text] [Related]
3. Serum levels of sFas and sFasL during chemotherapy of lung cancer. Naumnik W; Izycki T; Ossolinska M; Chyczewska E Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746 [TBL] [Abstract][Full Text] [Related]
4. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma. Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553 [TBL] [Abstract][Full Text] [Related]
5. Significance of Fas and Fas ligand in tuberculous lymphadenitis. Mustafa T; Mogga SJ; Mfinanga SG; Mørkve O; Sviland L Immunology; 2005 Feb; 114(2):255-62. PubMed ID: 15667570 [TBL] [Abstract][Full Text] [Related]
6. Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2. Yoshimura C; Nomura S; Kanazawa S; Kuwana M; Muramatsu M; Yamaguchi K; Fukuhara S J Cancer Res Clin Oncol; 2002 Nov; 128(11):581-8. PubMed ID: 12458337 [TBL] [Abstract][Full Text] [Related]
7. Soluble Fas ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS). Matute-Bello G; Liles WC; Steinberg KP; Kiener PA; Mongovin S; Chi EY; Jonas M; Martin TR J Immunol; 1999 Aug; 163(4):2217-25. PubMed ID: 10438964 [TBL] [Abstract][Full Text] [Related]
8. Clinical importance of circulating and cellular expression levels of Fas and Fas ligand in pediatric patients with lymphoproliferative malignancies. Hazar V; Berber Z; Pestereli E; Coskun M; Yesilipek A; Karpuzoglu G; Yegin O Pediatr Hematol Oncol; 2005; 22(3):247-56. PubMed ID: 16020109 [TBL] [Abstract][Full Text] [Related]
9. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Nagao M; Nakajima Y; Hisanaga M; Kayagaki N; Kanehiro H; Aomatsu Y; Ko S; Yagita H; Yamada T; Okumura K; Nakano H Hepatology; 1999 Aug; 30(2):413-21. PubMed ID: 10421649 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of bronchoalveolar lavage fluid from ARDS patients with regard to apoptosis. Lee KS; Choi YH; Kim YS; Baik SH; Oh YJ; Sheen SS; Park JH; Hwang SC; Park KJ Respir Med; 2008 Mar; 102(3):464-9. PubMed ID: 17988850 [TBL] [Abstract][Full Text] [Related]
11. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure. Nakae H; Narita K; Endo S J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600 [TBL] [Abstract][Full Text] [Related]
12. Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients. Shimizu M; Kondo M; Ito Y; Kume H; Suzuki R; Yamaki K Cancer Detect Prev; 2005; 29(2):175-80. PubMed ID: 15829378 [TBL] [Abstract][Full Text] [Related]
13. Circulating soluble Fas concentration in breast cancer patients. Ueno T; Toi M; Tominaga T Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768 [TBL] [Abstract][Full Text] [Related]
14. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. Matsuno H; Yudoh K; Watanabe Y; Nakazawa F; Aono H; Kimura T J Rheumatol; 2001 Jan; 28(1):22-8. PubMed ID: 11196534 [TBL] [Abstract][Full Text] [Related]
15. Serum levels of soluble molecules associated with evasion of immune surveillance: a study in biliary disease. Enjoji M; Yamaguchi K; Nakashima M; Ohta S; Kotoh K; Fukushima M; Kuniyoshi M; Tanaka M; Nakamuta M; Watanabe T; Nawata H Liver Int; 2004 Aug; 24(4):330-4. PubMed ID: 15287856 [TBL] [Abstract][Full Text] [Related]
16. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors. Kondera-Anasz Z; Mielczarek-Palacz A; Sikora J Apoptosis; 2005 Oct; 10(5):1143-9. PubMed ID: 16151647 [TBL] [Abstract][Full Text] [Related]
17. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment. Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929 [TBL] [Abstract][Full Text] [Related]
18. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer. Nadal C; Maurel J; Gallego R; Castells A; Longarón R; Marmol M; Sanz S; Molina R; Martin-Richard M; Gascón P Clin Cancer Res; 2005 Jul; 11(13):4770-4. PubMed ID: 16000573 [TBL] [Abstract][Full Text] [Related]
19. Seasonal changes of proapoptotic soluble Fas ligand level in allergic rhinitis combined with asthma. Mezei G; Lévay M; Sepler Z; Héninger E; Kozma GT; Cserháti E Pediatr Allergy Immunol; 2006 Sep; 17(6):444-9. PubMed ID: 16925690 [TBL] [Abstract][Full Text] [Related]
20. Measurement of soluble Fas antigen and ligand in circulating serum and intra-abdominal or cerebrospinal fluid during gastrointestinal or cerebrovascular surgery. Iwama H; Kato M; Ohmori S; Akimaru K; Tsutsumi K; Tohma J; Nakamura N J Crit Care; 2000 Sep; 15(3):119-25. PubMed ID: 11011825 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]